The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence

References

• Abbott PJ 2009. A review of the community reinforecement approach in the treatment of opioid dependence. J Psychoactive Drugs 41:379–385.
   PubMed Web of Science ®Google Scholar
• Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, . 2007. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol Assess 11:iii–iv, 1–85.
   PubMed Web of Science ®Google Scholar
• Agthe AG, Kim GR, Mathias KB, Hendrix CW, Chavez-Valdez R, Jansson L, . 2009. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics 123:e849–856.
   Web of Science ®Google Scholar
• Aldrich JV, McLaughlin JP 2009. Peptide kappa opioid receptor ligands: potential for drug development. AAPS J 11:312–322.
   PubMed Web of Science ®Google Scholar
• Alho H, Sinclair D, Vuori E, Holopainen A. 2007. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 88:75–78.
   PubMed Web of Science ®Google Scholar
• Amass L, Bickel WK, Crean JP, Blake J, Higgins ST. 1998. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology (Berlin) 136:217–225.
   PubMed Web of Science ®Google Scholar
• Amass L, Kamien JB, Reiber C, Branstetter S. 2000. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 60(Suppl 1):S6.
   Google Scholar
• Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. 2008a. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev:CD004147.
   Google Scholar
• Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. 2008b. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev:CD005031. DOI: 005010.001002/14651858. CD14005031.pub14651853.
   Google Scholar
• American Psychiatric Association Practice Guidelines. 2007. Treatment of Patients with Substance Use Disorders, Second edition. Am J Psychiatry 164:4(Suppl).
   PubMedGoogle Scholar
• Anglin MD, Almog IJ, Fisher DG, Peters KR. 1989. Alcohol use by heroin addicts: evidence for an inverse relationship. A study of methadone maintenance and drug-free treatment samples. Am J Drug Alcohol Abuse 15:191–207.
   PubMed Web of Science ®Google Scholar
• Arias A, Feinn R, Kranzler HR. 2006. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend 83:262–268.
   PubMed Web of Science ®Google Scholar
• Auriacombe M, Franques P, Tignol J. 2001. Deaths attributable to methadone vs buprenorphine in France. J Am Med Assoc 285:45.
   PubMed Web of Science ®Google Scholar
• Backmund M, Meyer K, Rothenhaeusler HB, Soyka M. 1998. Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. J Clin Psychopharmacol 18:257–258.
   PubMedGoogle Scholar
• Backmund M, Schutz CG, Meyer K, Eichenlaub D, Soyka M. 2003. Alcohol consumption in heroin users, methadone-substituted and codeine-substituted patients – frequency and correlates of use. Eur Addict Res 9:45–50.
   PubMed Web of Science ®Google Scholar
• Backmund M, Henkel C, Jordan F, Habsch J, Meyer K, Kääb S. 2005a. Das QT-Intervall während der Substitutionsbehandlung Heroinabhängiger [in German]. Suchtmed 7:161–164.
   Google Scholar
• Backmund M, Meyer K, Henkel C, Soyka M, Reimer J, Schutz CG. 2005b. Co-consumption of benzodiazepines in heroin users, methadone-substituted and codeine-substituted patients. J Addict Dis 24:17–29.
   PubMed Web of Science ®Google Scholar
• Backmund M, Schütz C, Mayer K, Edlin BR, Reimer J 2009. The risk of emergency treatment due to overdose in injection users. J Addict Dis 89:176–182.
   Google Scholar
• Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Allgulander C, . 2008. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 9:248–312.
   PubMed Web of Science ®Google Scholar
• Barnett PG, Rodgers JH, Bloch DA. 2001. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 96:683–690.
   PubMed Web of Science ®Google Scholar
• Beer B, Rabl W, Libiseller K, Giacomuzzi S, Riemer Y, Pavlic M. 2010. Impact of slow-release oral morphine on drug abusing habits in Austria (in German). Neuropsychiatry 24:108–117.
   Google Scholar
• Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, . 2002. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 22:211–215.
   PubMed Web of Science ®Google Scholar
• Berglund M, Thelander S, Jonsson E. 2003. Treating alcohol and drug abuse. An evidence based review. Weinheim: Wiley-VCH.
   Google Scholar
• Berrocoso E, Sanchez-Blazquez P, Garzon J, Mico JA. 2009. Opiates as antidepressants. Curr pharm Res 15:1612–1622.
   PubMed Web of Science ®Google Scholar
• Bickel WK, Amass L, Crean JP, Badger GJ. 1999. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berlin) 146:111–118.
   PubMed Web of Science ®Google Scholar
• Binder T, Vavrinkova B. 2008. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuroendocrinol Lett 29:80–86.
   PubMed Web of Science ®Google Scholar
• Blanken P, Hendriks VM, van Ree JM, van den Brink W. 2009. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction 105:300–308.
   PubMedGoogle Scholar
• Blanken P, van den Brink W, Hendriks VM, Huijsman IA, Klous MG, Rook EJ, . 2010. Heroin-assisted treatment in the Netherlands: History, findings, and international context. Eur Neuropsychopharmacology 20(Suppl 2):5105–5158.
   Google Scholar
• Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, . 1998. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95:9608–9613.
   PubMed Web of Science ®Google Scholar
• Boscarino JA, Rukstalis M, Hoffman SN, Han JJ, Erlich PM, Gerhard GS, Stewart F. 2010. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 105:1176–1782.
   PubMedGoogle Scholar
• Boulton DW, Arnaud P, DeVane CL. 2001. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther 70:48–57.
   PubMed Web of Science ®Google Scholar
• Brewer C, Wong VS. 2004. naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addict Biol 9:81–87.
   PubMed Web of Science ®Google Scholar
• Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. 2009. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse 35:68–72.
   PubMed Web of Science ®Google Scholar
• Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. 2006. Clozapine use and relapse of substance use disorder among patients with co-occuring schizophrenia and substance use disorders. Schizophr Bull 32:637–643.
   PubMed Web of Science ®Google Scholar
• Bunten H, Liang, W-J, Pounder D, Senevirantne C, Osselton MD. 2010. CYP2B6 and OPRMI gene variations predict methadone-related deaths. Addict Biol 16:142–144.
   Google Scholar
• Burns L, Randall D, Hall WD, Law M, Butler T, Bell J, . 2009. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction 104:1363–1372.
   PubMedGoogle Scholar
• Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. 1996. Methadone maintenance and addicts’ risk of fatal heroin overdose. Subst Use Misuse 31:177–196.
   PubMed Web of Science ®Google Scholar
• Carroll KM, Chang G, Behr H, Clinton B, Kosten TR. 1995. Improving treatment outcome in pregnant, methadone-maintained women. Am J Addict 4:56–59.
   Web of Science ®Google Scholar
• Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan DA, Frankforter TL, . 2001. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 58:755–761.
   PubMed Web of Science ®Google Scholar
• Castells X, Kosten TR, Capellà D, Vidal X, Colom J, Casas M. 2009. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials. Am J Drug Alcohol Abuse 35:339–349.
   PubMed Web of Science ®Google Scholar
• Charney DS, Sternberg DE, Kleber HD, Heninger GR, Redmond DE Jr. 1981. The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch Gen Psychiatry 38:1273–1277.
   PubMed Web of Science ®Google Scholar
• Chevillard L, Megarbane B, Faud FJ, Risede P, Decleves X, Mager D, . 2010. Mechanisms of respiratory insufficiency induced by methadone overdose in rats. Addict Biol 15:62–80.
   PubMedGoogle Scholar
• Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, . 2009. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10:113–130.
   PubMed Web of Science ®Google Scholar
• Cleary BJ, Donelly J, Strawbridge J, Gallagher PJ, Fahey T, Clarke M, Murphy DJ. 2010. Methadone dose and neonatal abstinence syndrome – systematic review and meta-analysis. Addiction 105:2071–2084.
   PubMed Web of Science ®Google Scholar
• Cleary M, Hunt G, Matheson S, Siegfried N, Walter G. 2008. Psychosocial intervetions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 23:CD001088.
   Google Scholar
• Cook S, Moeschler O, Katarzyna M, Yersin B. 1998. Acute opiate overdose: characteristics of 190 consecutive cases. Addiction 93:1559–1565.
   PubMed Web of Science ®Google Scholar
• Collins ED, Kleber HD, Whittington RA, Heitler NE. 2005. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. J Am Med Assoc 294:903–913.
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, . 2006. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 63:210–218.
   PubMed Web of Science ®Google Scholar
• Compton P, Ling W, Moody D, Chiang N. 2006. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend 82:25–31.
   PubMed Web of Science ®Google Scholar
• Condelli WS, Fairbank JA, Dennis ML, Rachal JV. 1991. Cocaine use by clients in methadone programs: significance, scope, and behavioral interventions. J Subst Abuse Treat 8:203–212.
   PubMed Web of Science ®Google Scholar
• Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, . 2007. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 11:iii–iv, 1–171.
   PubMedGoogle Scholar
• Corkery JM, Schifano F, Ghodse AH, Oyefeso A. 2004. The effects of methadone and its role in fatalities. Hum Psychopharmacol 19:565–576.
   PubMed Web of Science ®Google Scholar
• Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B, . 1997. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 14:529–534.
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, . 2005. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593–604.
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, . 2006. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80:668–681.
   PubMed Web of Science ®Google Scholar
• Crettol S, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, . 2008. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychaitry 32:1722–1727.
   PubMed Web of Science ®Google Scholar
• Curran HV, Kleckham J, Bearn J, Strang J, Wanigaratne S. 2001. Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: a dose-response study. Psychopharmacology (Berlin) 154:153–160.
   PubMed Web of Science ®Google Scholar
• Dahan A. 2006. Opioid-induced respiratory effects: new data on burprenorphine.
   Google Scholar
• Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, . 2006. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 96:627–632.
   PubMed Web of Science ®Google Scholar
• Dahan A, Aarts L, Smith TW. 2010. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 112:226–238.
   PubMed Web of Science ®Google Scholar
• Darke S, Hall W. 2003. Heroin overdose: Research and evidence-based intervention. J Urban Health 80:189–200.
   PubMed Web of Science ®Google Scholar
• Darke S, Ross J. 2002. Suicide among heroin users: rates, risk factors and methods. Addiction 97:1383–1394.
   PubMed Web of Science ®Google Scholar
• Darke S, Sims J, McDonald S, Wickes W. 2000. Cognitive impairment among methadone maintenance patients. Addiction 95: 687–695.
   PubMed Web of Science ®Google Scholar
• Darke S, Degenhardt L, Mattick R. 2007. Mortality amongst illicit drug users. Epidemiology, causes and intervention. Cambridge: Cambridge University Press.
   Google Scholar
• Davids E, Gastpar M. 2004. Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacol 14:209–216.
   PubMed Web of Science ®Google Scholar
• Davis PE, Liddiard H, McMillan TM. 2002. Neuropsychological deficits and opiate abuse. Drug Alcohol Depend 67:105–108.
   PubMed Web of Science ®Google Scholar
• Day E, Ison J, Strang J. 2005. Inpatient versus other settings for detoxification for opioid dependence. Cochrane Database Syst Rev:CD004580.
   PubMedGoogle Scholar
• De Jong CJ. 2005. General anaesthesia is patient-friendly in opioid antagonist detoxification treatment. Addiction 100:1742–1744.
   PubMedGoogle Scholar
• de Vos JW, Ufkes JG, Kaplan CD, Tursch M, Krause JK, van Wilgenburg H, . 1998. L-Methadone and D,L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations. Eur Addict Res 4:134–141.
   PubMed Web of Science ®Google Scholar
• Deamer RL, Wilson DR, Clark DS, Prichard JG. 2001. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis 20:7–14.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Gibson A, Mattick RP, Hall W. 2008. Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy. Drug Alcohol Rev 27:1–3.
   PubMed Web of Science ®Google Scholar
• De Leon G, Jainchill N 1991. Residential therapeutic communities for female substance abusers. Bull NY Acad Med 67:277–290.
   PubMedGoogle Scholar
• Dobler-Mikola A, Hättenschwiler J, Meili D, Beck T, Böni E, Modestin J. 2005. Patterns of heroin, cocaine, and alcohol abuse during long-term methadone maintenance treatment. J Subst Abuse Treat 29:259–265.
   PubMed Web of Science ®Google Scholar
• Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. 2005. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 100:1496–1509.
   PubMed Web of Science ®Google Scholar
• Drake RE, Xie H, McHugo GJ, Green AI. 2000. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 26:441–449.
   PubMed Web of Science ®Google Scholar
• Drake RE, O Neal EL, Wallach MA. 2008. A systematic review of psychosocial research on psychosocial interventions for people with co-occuring severe mental and substance use disorders. J Subst Abuse Treat 34:123–138.
   PubMed Web of Science ®Google Scholar
• Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Oto MW. 2008. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 165:179–187.
   PubMed Web of Science ®Google Scholar
• Eap CB, Buclin T, Baumann P. 2002. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 41:1153–1193.
   PubMed Web of Science ®Google Scholar
• EBDD (Europäische Beobachtungsstelle für Drogen und Drogensucht). 2009. Jahresbericht 2009: Stand der Drogenproblematik in Europa [in German]. Luxemburg: Amt für amtliche Veröffentlichungen der Europäischen Union.
   Google Scholar
• Ebner N, Rohrmeister K, Winklbaur B, Bauert A, Jagsch R, Peternell A, . 2007. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 87:131–138.
   PubMed Web of Science ®Google Scholar
• Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, . 2006. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 166:1280–1287.
   PubMed Web of Science ®Google Scholar
• Ehret GN, Desmeules JA, Broers B 2007. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Fas 6:289–303.
   Google Scholar
• Eissenberg T, Johnson RE, Bigelow GE, Walsh SL, Liebson IA, Strain EC, . 1997. Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend 45:81–91.
   PubMed Web of Science ®Google Scholar
• Elsner H. 2005. Kammertachykardien (“Torsade de Pointes) und weitere Herzrhytmusstörungen unter Methadonsubstitiution: Risikominderung durch Medikamentenumstellung [in German]. Suchtmed 7:257–263.
   Google Scholar
• Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. 2003. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev CD002208.
   PubMedGoogle Scholar
• Farre M, Mas A, Torrens M, Moreno V, Cami J. 2002. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 65:283–290.
   PubMed Web of Science ®Google Scholar
• Fareed A, Casarella J, Roberts M, Sleboda M, Amar R, Vayalapalli S, Drexler K. 2009. High dose versus moderate dose methadone maintenance: is there a better outcome? J Addict Dis 28:399–405.
   PubMed Web of Science ®Google Scholar
• Fareed A, Casarella J, Amar R, Vayalapalli S, Drexler K. 2010. Methadone maintenance dosing guideline for opioid dependence, a literature review. J Addict Dis 29:1–14.
   PubMed Web of Science ®Google Scholar
• Farrell M, Neeleman J, Gossop M, Griffiths P, Buning E, Finch E, . 1996. The legislation, organisation and delivery of methadone in 12 EU member states. Brussels: European Commission.
   Google Scholar
• Favrat B, Zimmermann G, Zullino D, Krenz S, Dorogy F, Muller J, . 2006. Opioid antagonist detoxification under anaesthesia versus traditional clonidine detoxification combined with an additional week of psychosocial support: a randomised clinical trial. Drug Alcohol Depend 81:109–116.
   PubMed Web of Science ®Google Scholar
• Ferri M, Davoli M, Perucci CA. 2010. Heroin maintenance for chronic heroin-dependent individuals: Cochrane Database Syst Rev CD00333410.
   PubMedGoogle Scholar
• Fingerhood MI, Thompson MR, Jasinski DR. 2001. A comparison of clonidine and buprenorphine in the outpatient treatment of opiate withdrawal. Subst Abuse 22:193–199.
   PubMedGoogle Scholar
• Fischer B, Cruz MF, Patra J, Rehm J. 2008. Predictors of methadone maintenance treatment utilization in a multisite cohort of illicit opioid users (OPICAN). J Subst Abuse Treat 34:340–346.
   PubMed Web of Science ®Google Scholar
• Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, Aschauer H. 2006. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 101:275–281.
   PubMed Web of Science ®Google Scholar
• Frick U, Rehm J, Zullino D, Fernando M, Wiesbeck G, Ammann J, Uchtenhagen A. 2010. Long-term follow-up of orally administered diacetylmorphine substitution treatment. Eur Addict Res 16:131–138.
   PubMedGoogle Scholar
• Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. 2000. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 50:427–440.
   PubMed Web of Science ®Google Scholar
• Foster DJ, Somogyi AA, White JM, Bochner F. 2004. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 57:742–755.
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, . 2003. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New Engl J Med 349:949–958.
   PubMed Web of Science ®Google Scholar
• Galanter M, Dermatis H, Glickman L, Maslansky R, Sellers MB, Neumann E, . 2004. Network therapy: decreased secondary opioid use during buprenorphine maintenance. J Subst Abuse Treat 26:313–318.
   PubMed Web of Science ®Google Scholar
• Garbutt JC. 2010. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des 16:2091–2097.
   PubMed Web of Science ®Google Scholar
• Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, . 2004. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 75:37–45.
   PubMed Web of Science ®Google Scholar
• Gil M, Sala M, Anguera I, Chapinal O, Cervantes M, Guma JR, . 2003. QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 92:995–997.
   PubMed Web of Science ®Google Scholar
• Gish EC, Miller JL, Honey BL, Johnson PN. 2010. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. Ann Pharmacother 44:343–351.
   PubMed Web of Science ®Google Scholar
• Glatt SJ, Bousman C, Wang RS, Murthy KK, Rana BK, Lasky-Su JA, . 2007. Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. Drug Alcohol Depend 90:159–165.
   PubMed Web of Science ®Google Scholar
• Gold MS, Pottash AC, Sweeney DR, Kleber HD. 1980. Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment. J Am Med Assoc 243:343–346.
   PubMed Web of Science ®Google Scholar
• Goldstein A, Herrera J. 1995. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug Alcohol Depend 40:139–150.
   PubMed Web of Science ®Google Scholar
• Gourevitch MN, Friedland GH. 2000. Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med 67:429–436.
   PubMed Web of Science ®Google Scholar
• Gowing L, Ali R, White J. 2006. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev:CD002025.
   Google Scholar
• Gowing L, Farrell M, Ali R, White JM. 2009. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev:CD002024.
   Google Scholar
• Gowing L, Ali R, White JM 2010. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database Syst Rev:CD002022.
   PubMedGoogle Scholar
• Grabowski J, O'Brien CP, Greenstein R, Ternes J, Long M, Steinberg-Donato S. 1979. Effects of contingent payment on compliance with a naltrexone regimen. Am J Drug Alcohol Abuse 6:355–365.
   PubMed Web of Science ®Google Scholar
• Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. 2003. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 60:81–85.
   PubMed Web of Science ®Google Scholar
• Green AI, Noordsy DL, Brunette MF, O'Keefe C. 2008. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat 34:61–71.
   PubMed Web of Science ®Google Scholar
• Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, . 2007. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry 61:101–110.
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Schuh KJ, Stine SM. 2003. Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study. Am J Addict 12:365–374.
   PubMed Web of Science ®Google Scholar
• Gross A, Marsch LA, Badger GJ, Bickel WK. 2006. A comparison between low-magnitude voucher and buprenorphine medication contingencies in promoting abstinence from opioids and cocaine. Exp Clin Psychopharmacol 14:148–156.
   PubMed Web of Science ®Google Scholar
• Gruber SA, Tzilos GK, Silveri MM, Pollack M, Renshaw PF, Kaufman MJ, . 2006. Methadone maintenance improves cognitive performance after two months of treatment. Exp Clin Psychopharmacol 14:157–164.
   PubMed Web of Science ®Google Scholar
• Gruber VA, McCance-Katz EF. 2010. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDs Rep 7:152–160.
   PubMedGoogle Scholar
• Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, . 2009. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 10:85–116.
   PubMed Web of Science ®Google Scholar
• Gutstein HB, Akil H 2001. Opioid analgesics. in: Goodman and Gilman's. The Pharmacological Basis of Therapeutics, 10th. Hardman JG, Limbirg LE, Gilman AG. New York: McGraw-Hill. 569–620.
   Google Scholar
• Haile CN, Kosten TA, Kosten TR. 2008. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse 34:355–381.
   PubMed Web of Science ®Google Scholar
• Hanon S, Seewald RM, Yang F, Schweitzer P, Rosman J. 2010. Ventricular arrhythmias in patients treated with methadone for opioid dependence. J Interv Card Electrophysiol 28:19–22.
   PubMed Web of Science ®Google Scholar
• Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. 2007. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 191:55–62.
   PubMed Web of Science ®Google Scholar
• Hartnoll RL, Mitcheson MC, Battersby A, Brown G, Ellis M, Fleming P, Hedley N. 1980. Evaluation of heroin maintenance in controlled trial. Arch Gen Psychiatry 37:877–884.
   PubMed Web of Science ®Google Scholar
• Havens JR, Latkin CA, Pu M, Cornelius LJ, Bishai D, Huettner S, . 2009. Predictors of opiate agonist treatment retention among injection drug users referred from a needle exchange program. J Subst Abuse Treat 36:306–312.
   PubMed Web of Science ®Google Scholar
• Honey BL, Benefield RJ, Miller JL, Johnson PN. 2009. Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. Ann Pharmacother 43:1506–1511.
   PubMed Web of Science ®Google Scholar
• Hser YI, Hoffman V, Grella CE, Anglin MD. 2001. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 58:503–508.
   PubMed Web of Science ®Google Scholar
• Hulse GK, Milne E, English DR, Holman CD. 1997. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 92:1571–1579.
   PubMed Web of Science ®Google Scholar
• Hulse GK, Milne E, English DR, Holman CD. 1998. Assessing the relationship between maternal opiate use and neonatal mortality. Addiction 93:1033–1042.
   PubMedGoogle Scholar
• Hulse GK, English DR, Milne E, Holman CD. 1999. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 94:221–229.
   PubMed Web of Science ®Google Scholar
• Hulse GK, Morris N, Arnold-Reed D, Tait RJ. 2009. Improving clinical outcomes in treating heroin dependence: Randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry 66:1108–1115.
   PubMed Web of Science ®Google Scholar
• Hulse GK, Ngo HT, Tait RJ. 2010. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone. Biol Psychiatry 68:296–302.
   PubMed Web of Science ®Google Scholar
• Iguchi MY, Lamb RJ, Belding MA, Platt JJ, Husband SD, Morral AR. 1996. Contingent reinforcement of group participation versus abstinence in a methadone maintenance program. Exp Clin Psychopharmacol 4:1–7.
   Google Scholar
• Ikeda K, Ide S, Han W, Hayashida M, Uhl GR, Sora I. 2005. How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci 26:311–317.
   PubMed Web of Science ®Google Scholar
• Janiri L, Mannelli P, Persico AM, Serretti A, Tempesta E. 1994. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend 36:139–145.
   PubMedGoogle Scholar
• Janetto PJ, Bratanow NC. 2009. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics 10:1157–1167.
   PubMedGoogle Scholar
• Jasinski DR, Johnson RE, Kocher TR. 1985. Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch Gen Psychiatry 42:1063–1066.
   PubMed Web of Science ®Google Scholar
• Johnson RE, Jones HE, Fischer G. 2003. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 70:S87–101.
   PubMed Web of Science ®Google Scholar
• Jones HE, Haug NA, Stitzer ML, Svikis DS. 2000. Improving treatment outcomes for pregnant drug-dependent women using low-magnitude voucher incentives. Addict Behav 25:263–267.
   PubMed Web of Science ®Google Scholar
• Jones HE, Haug N, Silverman K, Stitzer M, Svikis D. 2001. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend 61:297–306.
   PubMed Web of Science ®Google Scholar
• Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, . 2005. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 79: 1–10.
   PubMed Web of Science ®Google Scholar
• Jones HE, Martin PR, Heil SH, Kaltenbach K, Selby P, Coyle MG, . 2008. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 35:245–259.
   PubMed Web of Science ®Google Scholar
• Judson BA, Horns WH, Goldstein A. 1976. Side effects of levomethadone and racemic methadone in a maintenance program. Clin Pharmacol Ther 20:445–449.
   PubMed Web of Science ®Google Scholar
• Justo D. 2006. Methadone-induced long QT syndrome vs methadone-induced torsades de pointes. Arch Intern Med 166:2288; author reply 2289–2290.
   PubMedGoogle Scholar
• Kakko J, Svanborg KD, Kreek MJ, Heilig M. 2003. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 361:662–668.
   PubMed Web of Science ®Google Scholar
• Kakko J, Gronbladh L, Svanborg KD, von Wachenfeldt J, Ruck C, Rawlings B, . 2007. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 164:797–803.
   PubMed Web of Science ®Google Scholar
• Kakko J, Heilig M, Sarman I. 2008. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 96:69–78.
   PubMed Web of Science ®Google Scholar
• Kamien JB, Branstetter SA, Amass L. 2008. Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid-dependent patients. Heroin Addict Relat Clin Probl 10:5–18.
   Web of Science ®Google Scholar
• Kandall SR, Doberczak TM, Jantunen M, Stein J. 1999. The methadone-maintained pregnancy. Clin Perinatol 26:173–183.
   PubMedGoogle Scholar
• Kastelic A, Dubajic G, Strbad E. 2008. Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction 103:1837–1846.
   PubMed Web of Science ®Google Scholar
• Kerr T, Marsh D, Li K, Montaner J, Wood E. 2005. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug Alcohol Depend 80:329–335.
   PubMed Web of Science ®Google Scholar
• Khantzian EJ, Halliday KS, MacAuliffe WE. 1990. Addiction and the vulnerable self: Modified dynamic group therapy for substance abusers. New York: Guilford.
   Google Scholar
• Kharasch ED, Hoffer C, Whittington D, Sheffels P. 2004. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250–269.
   PubMed Web of Science ®Google Scholar
• Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, Robertson JR. 2010. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution. Br Med J 341:c3374. doi: 10.1136/bmj.c3172.
   Google Scholar
• Kleber HD, Riordan CE, Rounsaville B, Kosten T, Charney D, Gaspari J, . 1985. Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry 42:391–394.
   PubMed Web of Science ®Google Scholar
• Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T. 1987. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 13:1–17.
   PubMed Web of Science ®Google Scholar
• Kleber HD, Weiss RD, Anton RF Jr, George TP, Greenfield SF, Kosten TR, . 2007. Treatment of patients with substance use disorders, second edition. Am J Psychiatry 164:5–123.
   PubMed Web of Science ®Google Scholar
• Koob GF, Le Moal M 2006. Neurobiology of addiction. Amsterdam: Academic Press.
   Google Scholar
• Kosten TR, Gawin FH, Rounsaville BJ, Kleber HD. 1986. Cocaine abuse among opioid addicts: demographic and diagnostic factors in treatment. Am J Drug Alcohol Abuse 12:1–16.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Rounsaville BJ, Kleber HD. 1987. A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped? Arch Gen Psychiatry 44:281–284.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P. 1990a Desipramine and its 2-hydroxy metabolite in patients taking or not taking methadone. Am J Psyhiatry 147:1379–1380.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P. 1990b Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse 16:329–336.
   PubMed Web of Science ®Google Scholar
• Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS, . 2008. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics 122:e601–607.
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Mehler PS. 2006. QTc prolongation: methadone's efficacy-safety paradox. Lancet 368:556–557.
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. 2002. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 137:501–504.
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. 2003. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 23: 802–805.
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Rowan SB, Schmittner J, Bucher Bartelson B. 2007. Physician awareness of the cardiac effects of methadone: results of a national survey. J Addict Dis 26:79–85.
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Martin J, Stimmel B, Mehla D, Haigney MC. 2009. QTc interval screening in methadone treatment. Ann Intern Med 150: 387–395.
   PubMed Web of Science ®Google Scholar
• Kreek MJ, Hartman N. 1982. Chronic use of opioids and antipsychotic drugs. side effects, effects on endogenous opioids, and toxicity. Ann NY Acad Sci 398:151–172.
   PubMed Web of Science ®Google Scholar
• Kreek MJ, Hachey DL, Klein PD. 1979. Stereoselective disposition of methadone in man. Life Sci 24:925–932.
   PubMed Web of Science ®Google Scholar
• Kristensen K, Blemmer T, Angelo HR, Christrup LL, Drenck NE, Rasmussen SN, . 1996. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit 18: 221–227.
   PubMed Web of Science ®Google Scholar
• Krupitsky EM, Blokhina EA. 2010. Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry (in press).
   PubMedGoogle Scholar
• Krystal JH, Walker MW, Heninger GR. 1989. Intermittent naloxone attentuates the development of physical dependence on methadone in rhesus monkeys. Eur J Pharmacol 160:331–338.
   PubMed Web of Science ®Google Scholar
• Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. 2001. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Publ Health 91:774–780.
   PubMed Web of Science ®Google Scholar
• Lee TM, Pau CW. 2002. Impulse control differences between abstinent heroin users and matched controls. Brain Inj 16:885–889.
   PubMed Web of Science ®Google Scholar
• Leri F, Bruneau J, Stewart J. 2003. Understanding polydrug use: review of heroin and cocaine co-use. Addiction 98:7–22.
   PubMed Web of Science ®Google Scholar
• Levin FR, Fischman MW, Connerney I, Foltin RW. 1997. A protocol to switch high-dose, methadone-maintained subjects to buprenorphine. Am J Addict 6:105–116.
   PubMed Web of Science ®Google Scholar
• Ling W, Charuvastra C, Kaim SC, Klett CJ. 1976. Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study. Arch Gen Psychiatry 33:709–720.
   PubMed Web of Science ®Google Scholar
• Ling W, Wesson DR, Charuvastra C, Klett CJ. 1996. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 53:401–407.
   PubMed Web of Science ®Google Scholar
• Ling W, Amass L, Shoptaw S, Anton JJ, Hillhouse M, Babcock D, . 2005. A multi-center randomized trial of buprenorphine, naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trial Network. Addiction 100:1090–1100.
   PubMed Web of Science ®Google Scholar
• Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, . 2010. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. J Am Med Assoc 304:1578–1583.
   Google Scholar
• Lingford-Hughes AR, Welch S, Nutt DJ 2004. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Pharmacology. J Psychopharmacol 18: 293–335.
   PubMed Web of Science ®Google Scholar
• Lobmaier P, Kornor H, Kunoe N, Bjorndal A. 2008. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev:CD006140.
   PubMedGoogle Scholar
• Loeber S, Kniest A, Diehl A, Mann K, Croissant B. 2008. Neuropsychological functioning of opiate-dependent patients: a nonrandomized comparison of patients preferring either buprenorphine or methadone maintenance treatment. Am J Drug Alcohol Abuse 34:584–593.
   PubMed Web of Science ®Google Scholar
• Lotsch J, Geisslinger G. 2005. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 11:82–89.
   PubMed Web of Science ®Google Scholar
• Madlung-Kratzer E, Spitzer B, Brosch R, Dunkel D, Haring C. 2009. A double-blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow-release oral morphine versus methadone in opioid-dependent in-patients willing to undergo detoxification. Addiction 104:1549–1557.
   PubMed Web of Science ®Google Scholar
• Mammen K, Bell J. 2009. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin Pharmacother 10:2537–2544.
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Fellows B, Ailinani H, Pampati V. 2010. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Phys 13:401–435.
   PubMed Web of Science ®Google Scholar
• Mardsen J, Eastwood B, Bradbury C, Dale-Perera A, Farell M, Hammond P, . 2009. Effectiveness of community treatments for heroin abd crack cocaine addiction in England: a prospective, in-treatment cohort study. Lancet 374:1262–1270.
   PubMedGoogle Scholar
• Maremmani I, Canoniero S, Pacini M. 2000a. Methadone dose and retention in treatment of heroin addicts with bipolar I disorder comorbidity: preliminary results. Heroin Addict Relat Clin Prob 2:29–46.
   Google Scholar
• Maremmani I, Zolesi O, Aglietti M, Marini G, Tagliamonte A, Shinderman M, . 2000b. Methadone dose and retention during treatment of heroin addicts with Axis I psychiatric comorbidity. J Addict Dis 19:29–41.
   PubMed Web of Science ®Google Scholar
• Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A. 2005. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 11:44–49.
   PubMed Web of Science ®Google Scholar
• Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. 2005. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 95:915–918.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. 2003a. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 98:441–452.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. 2003b. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev:CD002207.
   Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. 2009. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev:CD 002209.
   PubMedGoogle Scholar
• Maxwell JC, Pullum TW, Tannert K. 2005. Deaths of clients in methadone treatment in Texas: 1994–2002. Drug Alcohol Depend 78:73–81.
   PubMed Web of Science ®Google Scholar
• Maxwell S, Shinderman M, Miner A, Bennet A. 2002. Correlation between Hepatitis C serostatus and methadone dose requirement in 1,163 methadone-maintained patients. Heroin Addict Relat Clin Prob 4:5–10.
   Google Scholar
• McCance-Katz EF, Sullivan LE. 2010. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. Am J Addict 19:4–16.
   PubMed Web of Science ®Google Scholar
• McCowan C, Kidd B, Fahey T. 2009. Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study. Br Med J 338:b2225.
   PubMedGoogle Scholar
• McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. 1993. The effects of psychosocial services in substance abuse treatment. J Am Med Assoc 269:1953–1959.
   PubMed Web of Science ®Google Scholar
• Meader N. 2010. A comparison of methadone, buprenorphine and alpha (2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis. Drug Alcohol Depend 108:110–114.
   PubMedGoogle Scholar
• Megarbane B, Hreiche R, Pirnay S, Marie N, Baud FJ, 2006. Does high-dose buprenorphine cause respiratory depression?: porrible mechanisms and therapeutic consequences. Toxicol Rev 25:79–85.
   PubMedGoogle Scholar
• Megarbane B, Buisien A, Jacobs F, Resiere D, Chevillard L, Vicaut E, Baud FJ. 2010. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. J Subst Abuse Treat 38:403–407.
   PubMedGoogle Scholar
• Meili D, Broers B, Bruggmann, Fink A, Hämmig R. 2008. Medical Recommendations for maintenance therapy in opioid dependence (Swiss Society of Addiction Medicine, in German). Suchtmed 10:29–53.
   Google Scholar
• Mello NK, Mendelson JH, Kuehnle JC, Sellers MS. 1981. Operant analysis of human heroin self-administration and the effects of naltrexone. J Pharmacol Exp Ther 216:45–54.
   PubMed Web of Science ®Google Scholar
• Messinis L, Lyros E, Andrian V, Katsakiori P, Panagis G, Georgiou V, . 2009. Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy. Hum Psychopharmacol 24:524–531.
   PubMed Web of Science ®Google Scholar
• Mintzer MZ. 2007. Effects of opioid pharmacotherapy on psychomotor and cognitive performance: A review of human laboratory studies of methadone and buprenorphine. Heroin Addict Relat Clin Prob 9:5–24.
   Google Scholar
• Mintzer MZ, Stitzer ML. 2002. Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend 67:41–51.
   PubMed Web of Science ®Google Scholar
• Mintzer MZ, Copersino ML, Stitzer ML. 2005. Opioid abuse and cognitive performance. Drug Alcohol Depend 78:225–230.
   PubMed Web of Science ®Google Scholar
• Mitchell TB, White JM, Somogyi AA, Bochner F. 2003. Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. Drug Alcohol Depend 72:85–94.
   PubMed Web of Science ®Google Scholar
• Mitchell TB, White JM, Somogyi AA, Bochner F. 2004. Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction 99:940–945.
   PubMed Web of Science ®Google Scholar
• Monte AA, Mandell T, Wilford BB, Tennyson J, Boyer EW. 2009. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis 28:226–231.
   PubMed Web of Science ®Google Scholar
• Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, . 2004. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 75:34–48.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Hachey DL, Kreek MJ, Irving CS, Klein PD. 1982. Quantitation of methadone enantiomers in humans using stable isotope-labeled [2H3]-, [2H5]-, and [2H8]Methadone. J Pharm Sci 71:40–43.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. 2007a. Drug misuse, psychosocial interventions. NICE Clinical Guideline 51, London.
   Google Scholar
• National Institute for Health and Clinical Excellence. 2007b. Drug misuse, Opioid detoxification. NICE Clinical Guideline 52, London.
   Google Scholar
• National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. 1978. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Arch Gen Psychiatry 35:335–340.
   PubMedGoogle Scholar
• Neuman MG, Monteiro M, Rehm J. 2006. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Subst Use Misuse 41:1395–1463.
   PubMed Web of Science ®Google Scholar
• Ngo HT, Tait RJ, Hulse GK. 2008. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation. Arch Gen Psychiatry 65:457–465.
   PubMed Web of Science ®Google Scholar
• Nicholis L, Bragaw L, Ruetsch C. 2010. Opioid dependence traetment and guidelines. J Manag Care Pharm 16:S14–21.
   Web of Science ®Google Scholar
• Nielsen S, Lintzeris N. 2008. The Use of sublingual buprenorphine-naloxone for reversing heroin overdose: a high-risk strategy that should not be recommended. Addiction 103: 2065–2066.
   PubMedGoogle Scholar
• Nigam AK, Ray R, Tripathi BM. 1993. Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treat 10:391–394.
   PubMed Web of Science ®Google Scholar
• O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, . 1998. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 105:100–105.
   PubMed Web of Science ®Google Scholar
• Okruhlica L, Klempova D. 2000. Hepatitis C infected patients and higher doses of methadone. Heroin Addict Relat Clin Prob 2:57–58.
   Google Scholar
• Oreskovich MR, Saxon AJ, Ellis ML, Malte CA, Reoux JP, Knox PC. 2005. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug Alcohol Depend 77:71–79.
   PubMed Web of Science ®Google Scholar
• Orman JS, Keating GM. 2009. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs 69:577–607.
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, . 2009. Diacetylmorphine versus methadone for the treatment of opioid addiction. New Engl J Med 361:777–786.
   PubMed Web of Science ®Google Scholar
• Pau CW, Lee TM, Chan SF. 2002. The impact of heroin on frontal executive functions. Arch Clin Neuropsychol 17:663–670.
   PubMed Web of Science ®Google Scholar
• Peles E, Adelson M. 2006. Gender difefrences and pregnant women in a methadone maintenance trestment (MMT) clinic. J Addict Dis 25:39–45.
   PubMed Web of Science ®Google Scholar
• Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. 2007. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study. Addiction 102:289–300.
   PubMed Web of Science ®Google Scholar
• Perrin-Terrin A, Pathak A, Lapeyre-Mestre M. 2010. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. Fundam Clin Pharmacol (in press).
   PubMedGoogle Scholar
• Perron BE, Bunger A, Bender K, Vaughn MG, Howard MO. 2010. Treatment guidelines for substance use disorders and serious mental illnesses: do they address co-occurring disorders? Subst Use Misuse 45:1262–1278.
   PubMed Web of Science ®Google Scholar
• Petitjean S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C, . 2001. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 62:97–104.
   PubMed Web of Science ®Google Scholar
• Petry NM, Bickel WK, Badger GJ. 1999. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. Clin Pharmacol Ther 66:306–314.
   PubMedGoogle Scholar
• Petry NM, Bickel WK, Badger GJ. 2000. A comparison of four buprenorphine dosing regimens using open-dosing procedures: is twice-weekly dosing possible? Addiction 95:1069–1077.
   PubMed Web of Science ®Google Scholar
• Pfohl DN, Allen JI, Atkinson RL, Knopman DS, Malcolm RJ, Mitchell JE, . 1986. Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. NIDA Res Monogr 67:66–72.
   PubMedGoogle Scholar
• Pirastu R, Fais R, Messina M, Bini V, Spiga S, Falconieri D, . 2006. Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend 83:163–168.
   PubMed Web of Science ®Google Scholar
• Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I. 2004. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 99:978–988.
   PubMed Web of Science ®Google Scholar
• Prendergast ML, Podus D, Chang E. 2000. Program factors and treatment outcomes in drug dependence treatment: an examination using meta-analysis. Subst Use Misuse 35:1931–1965.
   PubMed Web of Science ®Google Scholar
• Prendergast ML, Urada D, Podus D. 2001. Meta-analysis of HIV risk-reduction interventions within drug abuse treatment programs. J Consult Clin Psychol 69:389–405.
   PubMed Web of Science ®Google Scholar
• Preston KL, Bigelow GE, Liebson IA. 1990. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend 25:27–34.
   PubMed Web of Science ®Google Scholar
• Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. 1999. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend 54:127–135.
   PubMed Web of Science ®Google Scholar
• Prosser J, Cohen LJ, Steinfeld M, Eisenberg D, London ED, Galynker II. 2006. Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment. Drug Alcohol Depend 84:240–247.
   PubMed Web of Science ®Google Scholar
• Reece AS. 2007. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy 2:35.
   PubMed Web of Science ®Google Scholar
• Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH. 2006. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol 1:109–118.
   PubMedGoogle Scholar
• Rosner S, Leucht S, Lehert P, Soyka M. 2008. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 22:11–23.
   PubMed Web of Science ®Google Scholar
• Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. 2010. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 8: CD004332.
   Google Scholar
• SAMHSA (Substance Abuse and Mental Health Services Administration). 2001. National Household Survey on Drug Abuse (NHSDA) [http://www.samhsa.gov].
   Google Scholar
• Salamina G, Diedicue R, Vigna-Taglianti F, Jarre P, Schifano P, Bargagli AM, . 2010. Effectiveness of therapies for heroin addiction in retaining patients in treatment: results from the VEdeTTE study. Subst Use Misuse 45:2072–2092.
   Google Scholar
• San L, Arranz B, Martinez-Raga J. 2007. Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. Eur Addict Res 13:230–243.
   PubMed Web of Science ®Google Scholar
• Scherbaum N, Finkbeiner T, Leifert K, Gastpar M. 1996. The efficacy of L-methadone and racemic methadone in substitution treatment for opiate addicts – a double-blind comparison. Pharmacopsychiatry 29:212–215.
   PubMed Web of Science ®Google Scholar
• Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. 1997. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 54:713–720.
   PubMed Web of Science ®Google Scholar
• Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard HM, . 2000. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlld trial. J Am Med Assoc 283: 1303–1310.
   PubMed Web of Science ®Google Scholar
• Seifert J, Metzner C, Paetzold W, Borutzjy M, Passie T, Rollnik J, . 2002. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. Pharmacopsychiatry 35:159–164.
   PubMed Web of Science ®Google Scholar
• Shekelle PG, Woolf SH, Eccles M, Grimshaw J. 1999. Clinical guidelines: developing guidelines. Br Med J 318:593–596.
   PubMed Web of Science ®Google Scholar
• Silverman K, Higgins ST, Brooner RK, Montoya ID, Cone EJ, Schuster CR, . 1996. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry 53:409–415.
   PubMed Web of Science ®Google Scholar
• Silverman K, Wong CJ, Umbricht-Schneiter A, Montoya ID, Schuster CR, Preston KL. 1998. Broad beneficial effects of cocaine abstinence reinforcement among methadone patients. J Consult Clin Psychol 66:811–824.
   PubMed Web of Science ®Google Scholar
• Simmat-Durand L, Lejeune C, Gourarier L. 2009. Pregnancy under high-dose buprenorphine. Eur J Obstet Gynecol Reprod Biol 142:119–123.
   PubMed Web of Science ®Google Scholar
• Sinha R, Kimmerling A, Doebrick C, Kosten TR. 2007. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology (Berlin) 190:569–574.
   PubMed Web of Science ®Google Scholar
• Somogyi AA, Barratt DT, Coller JK. 2007. Pharmacogenetics of opioids. Clin Pharmacol Ther 81:429–444.
   PubMed Web of Science ®Google Scholar
• Soyka M. 2008a. Safety issues in methadone maintenance, part 1: Legal basis, mortality, and clinical results (in German). Suchtmed 10:7–27.
   Google Scholar
• Soyka M. 2008b. Safety issues in methadone maintenance therapy, part 2: Clinical and pharmacological aspects. (in German). Suchtmed 10:119–144.
   Google Scholar
• Soyka M, Rösner S. 2010a. Emerging drugs to treat alcoholism. Expert Opinion Emerg Drugs 15:695–711.
   PubMed Web of Science ®Google Scholar
• Soyka M, Rösner S 2010b. Nalmefene for treatment of alcohol dependence. Expert Opin Investig Drugs 19:1451–1459.
   PubMed Web of Science ®Google Scholar
• Soyka M, Zingg C. 2009. Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: clinical results from an open study. World J Biol Psychiatry 10:217–224.
   PubMed Web of Science ®Google Scholar
• Soyka M, Horak M, Dittert S, Kagerer S. 2001. Less driving impairment on buprenorphine than methadone in drug-dependent patients? J Neuropsychiatry Clin Neurosci 13:527–528.
   PubMedGoogle Scholar
• Soyka M, Hock B, Kagerer S, Lehnert R, Limmer C, Kuefner H. 2005. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial. J Clin Psychopharmacol 25:490–493.
   PubMed Web of Science ®Google Scholar
• Soyka M, Apelt SM, Lieb M, Wittchen HU. 2006. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 26:657–660.
   PubMed Web of Science ®Google Scholar
• Soyka M, Kranzler HR, Berglund M, Gorelick D, Hesselbrock V, Johnson BA, . 2008a. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. World J Biol Psychiatry 9:6–23.
   PubMed Web of Science ®Google Scholar
• Soyka M, Zingg C, Koller G, Kuefner H. 2008b. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol 11:641–653.
   PubMed Web of Science ®Google Scholar
• Spanagel R, Kirschke C, Tretter F, Holsboer F. 1998. Forced opiate withdrawal under anaesthesia augments and prolongs the occurrence of withdrawal signs in rats. Drug Alcohol Depend 52:251–256.
   PubMedGoogle Scholar
• Specka M, Finkbeiner T, Lodemann E, Leifert K, Kluwig J, Gastpar M. 2000. Cognitive-motor performance of methadone-maintained patients. Eur Addict Res 6:8–19.
   PubMed Web of Science ®Google Scholar
• Spencer L, Gregory M. 1989. Clonidine transdermal patches for use in outpatient opiate withdrawal. J Subst Abuse Treat 6:113–117.
   PubMed Web of Science ®Google Scholar
• Spiller H, Lorenz DJ, Bailey EJ, Dart RC. 2009. Epidemiological trends in abuse and misuse of presription opioids. J Addict Dis 28:130–136.
   PubMed Web of Science ®Google Scholar
• Simmel B, Cohen M, Sturiano V, Hanbury R, Korts D, Jackson G. 1983. Is treatment for alcoholism effective in persons on methadone maintenance? Am J Psychiatry 140:862–866.
   PubMedGoogle Scholar
• Stine SM, Freeman MS, Burns B, Charney DS, Kosten TR. 1992. The effect of methadone dose on cocaine abuse in methadone program. Am J Addict 1:294–303.
   Google Scholar
• Stine SM, Grillon CG, Morgan CA 3rd, Kosten TR, Charney DS, Krystal JH. 2001. Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine. Psychopharmacology (Berlin) 154:274–281.
   PubMed Web of Science ®Google Scholar
• Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH, 2002. Yohimbine-induced withdrawal and anxiety symptoms in opiod-dependent patients. Biol Psychiatry 15:642–651.
   Google Scholar
• Stitzer M, Bigelow G. 1978. Contingency management in a methadone maintenance program: availability of reinforcers. Int J Addict 13:737–746.
   PubMed Web of Science ®Google Scholar
• Stitzer ML, Bickel WK, Bigelow GE, Liebson IA. 1986. Effect of methadone dose contingencies on urinalysis test results of polydrug–abusing methadone-maintenance patients. Drug Alcohol Depend 18:341–348.
   PubMed Web of Science ®Google Scholar
• Stitzer ML, Iguchi MY, Felch LJ. 1992. Contingent take-home incentive: effects on drug use of methadone maintenance patients. J Consult Clin Psychol 60:927–934.
   PubMed Web of Science ®Google Scholar
• Stoller KB, Bigelow GE, Walsh SL, Strain EC. 2001. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berlin) 154:230–242.
   PubMed Web of Science ®Google Scholar
• Stotts AL, Dodrill CL, Kosten TR. 2009. Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 10:1727–1740.
   PubMed Web of Science ®Google Scholar
• Strain EC, Stitzer ML, Liebson IA, Bigelow GE. 1993a. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 119:23–27.
   PubMed Web of Science ®Google Scholar
• Strain EC, Stitzer ML, Liebson IA, Bigelow GE. 1993b. Methadone dose and treatment outcome. Drug Alcohol Depend 33:105–117.
   PubMed Web of Science ®Google Scholar
• Strain EC, Stitzer ML, Liebson IA, Bigelow GE. 1994. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 151:1025–1030.
   PubMed Web of Science ®Google Scholar
• Strain EC, Bigelow GE, Liebson IA, Stitzer ML. 1999. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. J Am Med Assoc 281:1000–1005.
   PubMed Web of Science ®Google Scholar
• Strassels SA. 2009. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm 15:556–562.
   PubMed Web of Science ®Google Scholar
• Stringer J, Welsh C, Tommasello A. 2009. methadone-associated Q-Z interval prolongation and torsade de pointes. Am J Health Syst Pharm 66:825–833.
   PubMed Web of Science ®Google Scholar
• Strang J, Mardsen J, Cummins M, Farrell M, Finch E, Gossop M, . 2000. Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibilty and 6-month outcome. Addiction 95:1631–1645.
   PubMed Web of Science ®Google Scholar
• Strang J, Metrablan N, Lintzeris N, Potts L, Carnwath T, Mayet S, . 2010. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatmnent (RIOTT): a randomized trial. Lancet 375:1885–1895.
   PubMed Web of Science ®Google Scholar
• Suffet F, Brotman R. 1984. A comprehensive care program for pregnant addicts: obstetrical, neonatal, and child development outcomes. Int J Addict 19:199–219.
   PubMed Web of Science ®Google Scholar
• Sullivan MA, Vosburg SK, Comer SD. 2006. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology (Berlin) 189:37–46.
   PubMed Web of Science ®Google Scholar
• Tait RJ, Ngo HT, Hulse GK. 2008. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat 35:116–124.
   PubMed Web of Science ®Google Scholar
• Termorshuizen F, Krol A, Prins M, van Ameijden EJ. 2005. Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users. Am J Epidemiol 161:271–279.
   PubMed Web of Science ®Google Scholar
• Threlkeld M, Parran TV, Adelman CA. Grey SF, Yu J. 2006. Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study. Am J Addict 15:186–191.
   PubMed Web of Science ®Google Scholar
• Tretter F, Burkhardt D, Bussello-Spieth B, Reiss J, Walcher S, Buchele W. 1998. Clinical experience with antagonist-induced opiate withdrawal under anaesthesia. Addiction 93:269–275.
   PubMed Web of Science ®Google Scholar
• Uchtenhagen A. 2010. Heroin-Assisted treatment in Switzerland: a case study in policy change. Addiction 105:29–37.
   PubMed Web of Science ®Google Scholar
• Unger A, Jung E, Winklbaur B, Fischer G. 2010. Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. J Addict Dis 29:217–230.
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime. 2006. 2006 World Drug Report. Vienna: UNODC.
   Google Scholar
• Umbricht A, Hoover DR, Tucker MJ, Leslie JM, Chaisson RE, Preston KL 2003. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug Alcohol Depend 69:263–272.
   PubMed Web of Science ®Google Scholar
• Valotassiou V, Wozniak G, Sifakis N, Demakopoulos N, Georgoulias P. 2008. Radiopharmaceuticals in neurological and psychiatric disorders. Curr Clin Pharmacol 3:99–107.
   PubMedGoogle Scholar
• van den Brink W, Haasen C. 2006. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry 51:635–646.
   PubMed Web of Science ®Google Scholar
• van den Brink W, van Ree JM. 2003. pharmacological treatments for heroin and cocaine addiction. Eur Neuropsychopharmacol 13:476–487.
   PubMed Web of Science ®Google Scholar
• van Dorp EL, Yassen A, Dahan A. 2007. Naloxone treatment in opioid addiction: th3 risks and benefits. Expert Opin Drug Saf 6:125–132.
   PubMed Web of Science ®Google Scholar
• Verdejo A, Toribio I, Orozco C, Puente KL, Perez-Garcia M. 2005. Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. Drug Alcohol Depend 78:283–288.
   PubMed Web of Science ®Google Scholar
• Verthein U, Nonorden-Kleij K, Degwitz P, Dilg C, Köhler WK, Passie T, . 2008. Long-term effects of heroin-assisted treatment in Germany. Addiction 103:960–966.
   PubMed Web of Science ®Google Scholar
• Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML 1995. Effects of buprenorphine and methadone in methadone-maintained subjetcs. Psychopharmacology (Berlin) 119:268–276.
   PubMed Web of Science ®Google Scholar
• Washton AM, Resnick RB, Rawson RA. 1980. Clonidine for outpatient opiate detoxification. Lancet i:1078–1079.
   Google Scholar
• Washton AM, Gold MS, Pottash AC. 1984. Successful use of naltrexone in addicted physicians and business executives. Adv Alcohol Subst Abuse 4:89–96.
   PubMedGoogle Scholar
• Wee S, Koob GF. 2010. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berlin) 210:121–135.
   PubMed Web of Science ®Google Scholar
• Welsh C. 2008. The use of buprenorphine to reverse opoid overdose deserves further evaluation. Addiction 103:2066–2067.
   PubMedGoogle Scholar
• Wesson DR, Smith DE. 2010. Buprenorphine in the treatment of opiate dependence. J Psychoactive Drugs 42:161–175.
   PubMed Web of Science ®Google Scholar
• West SL, O'Neal KK, Graham CW. 2000. A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse 12:405–414.
   PubMedGoogle Scholar
• Wilson RS, Di George WS. 1993. Methadone combined with clonidine versus clonidine alone in opiate detoxification. J Subst Abuse Treat 10:529–535.
   PubMed Web of Science ®Google Scholar
• Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer G. 2008a. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 103:1429–1440.
   PubMed Web of Science ®Google Scholar
• Winklbaur B, Jung E, Fischer G. 2008b. Opioid dependence and pregnancy. Curr Opin Psychiatry 21:255–259.
   PubMedGoogle Scholar
• Wittchen HU, Apelt SM, Soyka M, Gastpar M, Backmund M, Golz J, . 2008. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients. Drug Alcohol Depend 95: 245–257.
   PubMed Web of Science ®Google Scholar
• Wobrock T, Soyka M. 2008. Pharmacotherapy of schizophrenia with comorbid substance use disorder – reviewing the evidence and clinical recommendations. Prog Neuropsychopharmacol Biol Psychiatry 32:1375–1385.
   PubMed Web of Science ®Google Scholar
• Woody GE, Luborsky L, McLellan AT, O'Brien CP, Beck AT, Blaine J, . 1983. Psychotherapy for opiate addicts. Does it help? Arch Gen Psychiatry 40:639–645.
   PubMed Web of Science ®Google Scholar
• Woody GE, McLellan AT, O'Brien CP. 1984. Treatment of behavioral and psychiatric problems associated with opiate dependence. NIDA Res Monogr 46:23–35.
   PubMedGoogle Scholar
• Woody GE, McLellan AT, Luborsky L, O'Brien CP. 1987. Twelve-month follow-up of psychotherapy for opiate dependence. Am J Psychiatry 144:590–596.
   PubMed Web of Science ®Google Scholar
• Woody GE, McLellan AT, Luborsky L, O'Brien CP. 1995. Psychotherapy in community methadone programs: a validation study. Am J Psychiatry 152:1302–1308.
   PubMed Web of Science ®Google Scholar
• Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, . 2008. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. J Am Med Assoc 300:2003–2011.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2004. The World Health Report 2004. Geneva: WHO.
   Google Scholar
• Yen MH, Ko HC, Tang FI, Lu RB, Hong JS. 2006. Study of hepatotoxicity of naltrexone in the treatment of alcoholism. Alcohol 38:117–120.
   PubMed Web of Science ®Google Scholar
• Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ. 2010. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann NY Acad Sci 1187:184–207.
   PubMed Web of Science ®Google Scholar
• Ziedonis DM, Amass L, Steinberg M, Woody G, Krejci J, Annon JJ, . 2009. Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug Alcohol Depend 99:28–36.
   PubMed Web of Science ®Google Scholar
• Zukin RS, Sugarman JR, Fitz-Syage ML, Gardner EL, Zukin SR, Gintzler AR. 1982. Naltrexone-induced opiate receptor supersensitivity. Brain Res 245:285–292.
   PubMed Web of Science ®Google Scholar